Abstract Although outpatient knee arthroscopy is probably by far the most frequently performed orthopaedic procedure, there are limited guidelines or consensus concerning the peroral postoperative pain management. A diversity of analgesics both in potency and action is prescribed. The purpose of the present investigation was to grade the pain and need for rescue medication during the first 4 days after the knee arthroscopy, comparing a conventional nonsteroidal anti-inflammatory drug (NSAID) with a selective cox-II-inhibitor (coxib) as postoperative pain medication. One hundred and twenty-two patients scheduled for primary elective knee arthroscopy in general anaesthesia were randomised to either a NSAID (lornoxicam) or a selective cox-II-inhibitor (rofecoxib) postoperatively. Pain ratings and the need for rescue medication were followed for four consecutive days. Side effects were also registered. The need for rescue analgesics was highest the evening after surgery, when 42% of patients required one, or more, oral additional analgesics. The use of rescue medication decreased with time and 30, 25, 16 and 11% of the patients required additional analgesics for day 1 to 4, respectively, still 50% of all patients required at some point one or more rescue analgesics. Overall pain ratings were low, and showed similar pattern with evening and day, 50% of all patients required at some point one or more rescue analgesics. We found, however, no differences in pain ratings, or need for rescue analgesics between the two groups, conventional NSAID and coxib as well as no difference in side-effect profile. In conclusion, patients do require proper pain management also after minor outpatient surgical procedures such as knee arthroscopy. The traditional NSAIDs seem to be the first choice for analgesic and anti-inflammatory effects, when needed after elective arthroscopy of the knee.
Introduction
In outpatient surgery, methods to obtain safe and efficacious pain relief after discharge are demanded, not the least to allow early mobilisation [16, 23] . A multi-modal analgesic approach has become more or less the golden standard perioperatively. There is today no consensus as to the pain management postoperatively and after discharge.
One of the most frequent procedures in orthopaedic surgery is the outpatient knee arthroscopy. Previous studies have focused on mapping the peri-and postoperative pain pattern in accordance to the chosen anaesthesia [8, 10, 12] . There are, however, today limited guidelines concerning the peroral postoperative pain management of the knee arthroscopy. Various drugs are prescribed, from paracetamol only, by combinations with dextroprophoxiphene or codeine, to morphine. In addition to or as an alternative to these, an anti-inflammatory drug is prescribed frequently.
The introduction of the more selective cox-IIinhibitors (coxibs) was for some years heavily promoted because of their potentially lower side-effect profile. One of the most popular, rofecoxib, has been shown more effective than diclofenac, traditional oxycontin/paracetamol as well as codeine for the treatment of acute pain and with a better side-effect profile [2, 3, 13] . Further studies have, however, been requested in order to prove more accurately the costbenefit of these new, more expensive anti-inflammatory agents in postoperative pain management [5] . Even more important, recently, major concerns have been raised as to the unselective use of the coxibs also in the perioperative period [18] . The present study was initiated while the coxibs had no restrictions for use.
The aim was to compare the use of a classical nonsteroidal anti-inflammatory agent with the use of a coxib following elective arthroscopy of the knee having the need for rescue analgesia, as a primary study objective and pain rating as secondary study variable.
Materials and methods
After an obtained approval from the Ethics Committee of the Karolinska Hospital (no 03-133, 2003-07-10), and informed consent from the subjects, 122 ASA I-II patients scheduled for primary elective knee arthroscopy in general anaesthesia were enrolled in the study. The female/male ratio was 46/76.
The patients, mean age 48 (18-70 years) and weight 79 (50-110 kg) were randomly allocated to receive a conventional NSAID (lornoxicam) or a coxib (rofecoxib) by envelope technique. The need for rescue analgesia and pain ratings during the four first postoperative days were followed. A questionnaire, including VAS scales (non-interrupted, 0-10 cm) was used (Fig. 1) . The VAS scale is considered as a reliable tool in pain measurement [22] .
All patients were anaesthetised according to the standard departmental routines. As premedication cyclolozine 50 mg was given orally. Anaesthesia was induced with propofol and fentanyl (0.1 mg) followed by the placement of a laryngeal mask airway. Maintenance was achieved by oxygen in nitrous oxide (1:2), and sevoflurane that was titrated to clinical needs. At the end of surgery anaesthetic gases were discontinued and replaced by oxygen only, until the patient regained consciousness. All patients had 10 ml local anaesthesia (lidocaine 10 mg/ml with adrenaline) administered at the arthroscopy portals prior to incision. At the end of surgery 10 ml lidocaine 10 mg/ml with adrenaline and 50 lg fentanyl was injected in the joint.
In the recovery room all patients were given orally 1 g paracetamol and an anti-inflammatory agent in accordance to randomisation as soon as possible after waking up. All patients were discharged after oral and written information about how to take the recommended standard daily doses of the randomised drug; 16 mg lornoxicam, or 50 mg rofecoxib. Pain assessments (VAS scale) were made frequently, the first 30 min after surgery. Rescue medication, dextropropoxiphene 100 mg (up to three times), was provided on request, or if VAS > 4.
At discharge all patients were asked to fill in the questionnaire and were given a package of randomised drug treatment for the following 4 days (8 mg lornoxicam twice daily or 50 mg rofecoxib once daily) and were instructed to take this therapy regardless of pain, in order to facilitate the recovery process. All patients were also provided with paracetamol up to 4 g daily as primary analgesic rescue medication and, as a secondary rescue, if needed, dextropropoxyphene 100 mg up to four tablets a day. The need for rescue medicaQuestions in questionnaire. tion, pain grading and occurrence of side effects were recorded on a questionnaire that was sent back to the hospital for evaluation.
Statistics
Patient demographics are presented as mean and standard deviations. VAS ratings and need for rescue analgesia values are presented as median and range. Differences between groups were studied by nonparametric tests; Chi-square test or Mann-Whitney U-test when appropriate. The number of patients (61 in each group) was determined by a power analysis based on the assumption; a response rate for no need for rescue analgesics in the conventional NSAID group of 45% and a clinical relevant further reduction being an absolute increase of 15%, corresponding to 60% of patients not requiring rescue analgesia during the first postoperative day with a power of 90% at P < 0.05.
Results
All surgery and anaesthesia was uneventful and all patients were discharged in accordance to the routines of the department. Surgeries performed are shown in Table 1 . In the recovery area pain was low overall, pain rating at 30 min median 0 (0-6).
The need for rescue analgesics was highest in the evening after surgery when 42% of patients required one or more oral rescue analgesics. The need for rescue analgesics decreased thereafter with time and 30, 25, 16 and 11% of the patients required rescue analgesics for day 1 to 4, respectively. Overall pain ratings were low and showed similar pattern with a rapid decrease over time. A pain rating of more than four was recalled by 20% of patients during the first evening after surgery and 16, 6, 4 and 2% during the first four postoperative days. Accumulated, 4 days VAS, of more than 10/40 was reported from 25 (21%) patients.
Sixty-one patients (50%) needed at some point one or more rescue analgesics. There was, however, no difference found in the primary study variable, the need for rescue medication between the two groups studied; 30 NSAID and 31 coxib patients had not taken any further analgesics than the prescribed anti-inflammatory drug during the first four postoperative days (ns) ( Table 2) .
Pain assessed by VAS was also similar between the groups (Table 3) . Accumulated pain-rating day 1-4, did not differ between the NSAID patients median 7 (0-39) and the coxib patients 7 (0-33), respectively (ns) (' Table 3 ).
Side-effects were reported in 20 patients of all, 10 patients in each group. Most commonly recalled side effect was gastrointestinal symptoms, second most common fatigue and third general dizziness. One patient each recalled sweating, dry mouth, palpitations, chest discomfort, leg oedema and one had rash.
Patients overall satisfaction with their pain management after discharge was high and did not differ between the groups, 8.9 (0-10) and 9.0 (5-10) for NSAID and coxib patients, respectively. The total number of patients 122; with 61 in each group 0  9  11  13  10  23  26  28  31  32  32  1  18  8  17  19  11  12  11  13  12  17  2  9  17  8  17  12  13  11  9  10  5  3  9  8  6  4  7  6  5  5  4  2  4  2  7  6  3  3  2  2  1  1  3  5  5  2  3  3  2  0  2  1  2  6  4  0  3  1  0  0  0  0  7  3  1  3  2  1  2  1  1  8  2  5  1  2  1  9  1  1  1  10  1 The total number of patients 122 with 61 in each group
There are two main findings in the present study. First it acknowledges the fact that minor surgical procedures, such as, elective outpatient knee arthroscopy is associated with discomfort requiring medication for pain during several days after surgery. Second there is, indeed, no further benefit in using the new more costly and potentially risky coxibs for regular medication against pain and inflammation, following outpatient surgical arthroscopy [1, 19] . Vioxx Ó (rofecoxib) was released on the Swedish market in the year 2000 indicated for pain management in arthritis, and a year after, it was the top-selling product. During the first years of the new millennium rofecoxib as well as other coxibs were also strongly promoted for acute postoperative pain management. This study was started before the alert on adverse cardiovascular events related to the coxibs [1, 19] We still find it of importance to report our overall results both from an ethical point of view, as well as some of the results can be seen and used from a more general pain management perspective, especially as the coxibs still are in common use.
In this study we chose an anti-inflammatory agent as the first line medication in order to give both pain relief, and to limit postoperative synovitis. The aim of our study was to compare the effect of a traditional NSAID to a coxib during the first 4 days following surgery, in seemingly equipotent doses [21] . Rofecoxib is known to have a long duration of action and is used as one dose a day only, whereas, the conventional NSAIDs have shorter duration of action and is usually prescribed twice, or even three times a day as for diclofenac. The present study was started with the hypothesis coxibs being more effective with respect to 24 h pain relief, and therefore a reduced need for rescue analgesia, as compared to standard NSAIDs, with known shorter duration of action, as suggested by some [2, 3] . Our results, with regard to the pain alleviating effects may indeed not be that surprising. We studied what is considered equipotent daily doses. Also, others have shown similar analgesic efficacy for traditional NSAIDs and coxibs, and there are also others suggesting that the conventional NSAIDS are the rational choice for short-term acute pain management before the coxibs [4, 11] . A recent article questions the use of coxibs as an alternative to traditional NSAIDs in another respect; coxibs are detrimental to tissue-level repair in animal models of acute injury. Specifically they have been shown to impair the return of mechanical strength following acute injury to bone joint and tendon [25] .
The present study is, of course, far too small to evaluate safety. When considering the side-effects, the duration of therapy should of course be taken into account. The risk for gastrointestinal side effects from short-term postoperative use of NSAIDs have been questioned [14] . The risk for a severe NSAID-induced gastrointestinal bleeding during a maximum 4-day treatment in preferably young and otherwise healthy patients (ASA I-II) may be considered very low. The surgical stress of a knee arthroscopy is probably also low, not enhancing ulcer development. The coxibs are associated with serious and potentially fatal side effects, mainly from the cardiovascular system. The majority of cardiovascular events related to coxibs were reported in long term/chronic use. There are, however, reports on cardiovascular adverse events following postoperative treatment with coxibs [9] . Although, the negative cardiac vascular outcome was reported following heart surgery, the potential procoagulant effects has also been suggested just after one dose in ordinary patients undergoing minor surgery [17] . As expected we could see no difference in side effects between the two groups studied. This should of course be seen in the perspective of the limited number of patients and days studied.
Knee arthroscopy is one of the most common orthopaedic outpatient procedures and finding ways by which the pain management could be optimised during and shortly after surgery are described by several authors [7, 10, 24] . However, there are limited guidelines and variations are great in pain management in the postoperative phase and after discharge. We found rescue analgesia requiring pain in more than 25% of the patients studied during the first 48 h following surgery which is similar to findings by other authors [15, 20] . In this study we considered a pain rating of four or more to be unacceptable and thus, rescue requiring medication, according to our hospital routine. The chosen level for compulsory medication can be questioned as high [6] , but in the outpatient situation this may be tolerated if you have to consider the effects on heavy pain medication close to discharge. Naturally all patients got rescue medication on request, regardless of pain rating.
Postoperative pain after knee arthroscopy does not seem to be so severe motivating the prescription of heavy analgesics. Probably it is sufficient with a combination of paracetamol and NSAID, maybe enhanced by raising the limb and using crutches for the first few days. It is, however, of importance to inform the patient that pain during the first 2 days after surgery usually requires medication to avoid false expectations.
We did not include any cost benefit evaluation into the present study protocol. Just utilising the direct cost associated to the prescribed drugs the NSAID is a valid choice in terms of cost-minimisation. In Sweden the 24 h cost for the coxib is twice that of a regular NSAID (FASS 2005).
Summary and conclusion
The need for proper pain management is of importance also after minor minimal invasive procedures such as elective arthroscopy of the knee. Although, an anti-inflammatory drug was prescribed as a base medication, more than every third of patients did take additional rescue analgesics during the first evening following surgery and the first postoperative day. There were, however, no difference in the need for rescue analgesia or pain rating between the two groups, conventional NSAID and coxib, as well as no difference in side-effect profile. The traditional NSAIDs seem to be the first choice for analgesic and antiinflammatory effects when needed after elective arthroscopy of the knee.
